Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Cytology

Cytopathology in focus—Use of cytologic material for ancillary studies in respiratory pathology: Begin with the end in mind

August 2024—Case. A 58-year-old female patient undergoes robotic endobronchial ultrasound-guided fine-needle aspiration for a peripherally located right upper lobe stellate-shaped lung lesion with ground-glass opacification. Rapid onsite evaluation (ROSE) assessments were adequate on four Diff-Quik (DQ) smears that were prepared for evaluation. One slide was cover-slipped for diagnostic purposes and the remaining slides were retained, uncovered. The cytopathologist requested additional material for further ancillary studies. The needle was rinsed in CytoLyt solution used to prepare a cell block from the cell pellet, and the residual supernatant was stored (at -80°C) for possible future molecular studies. The cell block cellularity was adequate, and the malignant cell population represented 50 percent of the sampled cells.

Cytopathology in focus: Reporting salivary gland cytopathology—what’s new in Milan ed. 2?

August 2024—The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a widely endorsed and increasingly adopted standardized reporting system for salivary gland fine-needle aspiration biopsy specimens. The inaugural edition published in 2018 was inspired by the Bethesda cervicovaginal and thyroid reporting systems. The MSRSGC sought to facilitate clear and consistent communication between pathologists and the clinical team, thereby enhancing patient-centered decision-making and therapeutic interventions and assisting inter- and intralaboratory comparisons.

Cytopathology in focus—Low-grade pancreatic neuroendocrine tumors in small samples: Grading challenges

August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.

HPV test self-collection set in motion

July 2024—With the Food and Drug Administration approval in May of two HPV self-collection devices for use in clinic settings, physicians in and out of the laboratory are optimistic the approach can reach underscreened patients, even if FDA approval is only a first step.

Triage for HPV screen-positives gets a boost

June 2024—When it comes to detecting cervical precancer (CIN3), p16/Ki-67 dual stain testing cuts down on the number of colposcopies compared with using Pap cytology to triage HPV-positive patients. “Using cytology [for triage], you need to do about 32 colposcopies to identify one cervical precancer [CIN3]. If you were to switch to dual stain, it cuts it in half,” says Thomas Lorey, MD, senior consultant and former director of laboratory services for Kaiser Permanente Northern California, from which much of the data underpinning the guidelines on cervical cancer screening and management have been collected. Dr. Lorey and others are coauthors of new clinical management dual stain test recommendations, released in March by the member organizations of the Enduring Consensus Cervical Cancer Screening and Management Guidelines effort. The new recommendations address only the Roche CINtec Plus Cytology test, which detects both p16 and Ki-67 and was approved by the Food and Drug Administration in 2020.

LGBT+ health: changes, challenges in cytopathology

June 2024—Screening in transgender men with cervices and in transgender women with neovaginas was the focus of a CAP23 session that highlighted screening recommendations and morphologic challenges such as detecting high-grade dysplasia in a background of atrophy (trans men) and dysplasia risks (trans women)—and EHR-related improvements for both.

Cytopathology in focus—POU2F3: A new IHC marker for small cell lung cancer with low neuroendocrine marker expression

May 2024—Classically, immunohistochemical expression of small cell lung cancer (SCLC) is characterized by strong expression of neuroendocrine markers, notably synaptophysin, chromogranin A, insulinoma-associated protein 1 (INSM1), and CD-56. However, up to 20 percent of SCLCs demonstrate low or no expression of neuroendocrine (NE) markers by IHC and are termed “NE-low/negative.”

Cytopathology in focus: How to approach cytology of unknown primary

August 2023—We discuss in this article a common problem that all cytopathologists come across frequently in their practice: tumors of unknown primary origin involving body fluids and other sites. Metastatic tumor cells can disseminate and colonize discontinuous secondary body sites.1 Such tumor metastases may be the patient’s initial presenting complaint to a family physician for deep-seated tumor primaries such as ovaries, pancreas, liver, and certain non-obstructive gastrointestinal tumors.

MARKETPLACE

TRENDING